首发精神病缓解后减量抗精神病药:复发风险与D2受体亲和力相关而非减量速度
本研究在227例首发精神病缓解后减量抗精神病药的患者中,考察18个月内复发风险与减量速度及药物D2受体亲和力的关系。结果显示减量速度不预测复发,而高D2亲和力拮抗剂使用者复发风险约为其他药物使用者的两倍,且减量结束至复发的时间更短。
要点
- 减量速度(以奥氮平当量mg/日计)未预测复发风险(z=0.989,p=0.323)。
- 与高D2亲和力拮抗剂相比,低D2亲和力拮抗剂(OR=0.48,p=0.035)和部分D2激动剂(OR=0.44,p=0.023)复发风险更低。
- 高D2亲和力拮抗剂使用者减量结束至复发平均280天,短于低D2亲和力拮抗剂351天(p=0.027)和部分D2激动剂357天(p=0.040)。
核心结论
- 在首发精神病缓解后减量抗精神病药的人群中,药物D2受体亲和力比减量速度更能预测精神病性复发风险。
- 高D2亲和力抗精神病药使用者的复发风险约为其他类型抗精神病药使用者的两倍。
研究设计与样本
- 研究纳入227例首发精神病缓解后减量抗精神病药的个体,随访缓解后最初18个月。
- 复发采用基于阳性与阴性症状量表、因精神病住院或治疗精神科医生明确临床判断的共识标准二分类定义。
- 减量速度以奥氮平当量mg/日计算,即减量起止剂量差除以间隔天数;药物分为部分D2激动剂及低或高D2亲和力拮抗剂。
- 采用 logistic 回归与 Cox 比例风险回归,控制年龄、性别、大麻使用、首发精神病病程,并用逆概率治疗加权平衡三组D2亲和力药物的临床与社会人口学特征差异。
主要发现
- 随访期间45.8%(N=104)的参与者在减量后经历复发。
- 平均减量速度为75天内10 mg奥氮平当量,平均减量持续时间124天(范围6-334天)。
- logistic 回归显示减量速度不预测复发风险(z=0.989,p=0.323)。
- 与高D2亲和力拮抗剂使用者(N=57)相比,低D2亲和力拮抗剂使用者(N=116)复发风险更低(z=-2.104;OR=0.48,p=0.035),部分D2激动剂使用者(N=54)复发风险也更低(z=-2.278,OR=0.44,p=0.023)。
- 高D2亲和力拮抗剂使用者减量结束至复发的平均时间(280天)短于低D2亲和力拮抗剂使用者(351天,p=0.027)和部分D2激动剂使用者(357天,p=0.040)。
关键数值与推荐
- 复发定义:基于阳性与阴性症状量表的共识标准、因精神病住院或治疗精神科医生的明确临床判断。
- 药物D2亲和力分组例数:高D2亲和力拮抗剂N=57,低D2亲和力拮抗剂N=116,部分D2激动剂N=54。
- 减量速度计算单位为奥氮平当量mg/日;平均减量速度10 mg奥氮平当量/75天,平均减量持续时间124天(范围6-334天)。
临床怎么用
- 为首发精神病患者选择抗精神病药时,应将减量后复发风险与药物D2受体亲和力纳入考量。
- 对使用强D2拮抗剂且首发精神病已缓解的患者,减量期间需要额外监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
While antipsychotic maintenance treatment effectively prevents relapse after a first psychotic episode, many remitted antipsychotic users wish to reduce or discontinue their medication, due to side effects, long-term health concerns, stigma, or the desire to regain autonomy. Current guidelines suggest gradual tapering, but what the optimal speed of this tapering should be, especially in patients who remitted from a first psychotic episode, remains unclear. Furthermore, D2 receptor affinity of the antipsychotic drug may also affect relapse risk. This study examined relapse risk and time to relapse, within the first 18 months after remission from a first psychotic episode, in 227 individuals who tapered antipsychotic medication. Relapse was defined dichotomously using consensus criteria based on the Positive and Negative Syndrome Scale, hospitalization for psychosis, or explicit clinical judgement of the treating psychiatrist. Tapering speed (in olanzapine equivalents mg/day) was calculated as the difference of antipsychotic dose between the start and the end of tapering, divided by the number of days in between. Antipsychotics were classified into partial D2 agonists, or antagonists with low or high D2 affinity. Logistic and Cox proportional hazards regression analyses were controlled for age, sex, cannabis use, and duration of first psychotic episode, as well as for differences in clinical and sociodemographic characteristics between the three drug D2 affinity groups using inverse probability of treatment weighting. During the follow-up period, 45.8% (N=104) of participants experienced a relapse after tapering. The average tapering speed was 10 mg olanzapine equivalents over 75 days, with an average tapering duration of 124 days (range: 6-334 days). Logistic regression analysis showed that the tapering speed did not predict the risk of relapse (z=0.989, p=0.323). Compared with users of high D2 affinity antagonists (N=57), patients using low D2 affinity antagonists (N=116) and partial D2 agonists (N=54) had a lower risk of relapse (respectively, z=-2.104; odds ratio, OR=0.48, p=0.035; and z=-2.278, OR=0.44, p=0.023). Users of high D2 affinity antagonists had a shorter time between the end of tapering and relapse (mean: 280 days) than low D2 affinity antagonist users (mean: 351 days, p=0.027) and partial D2 agonist users (mean: 357 days, p=0.040). Thus, D2 receptor affinity of the antipsychotic was more important than tapering speed in predicting psychotic relapse risk in individuals remitted from a first psychotic episode. Users of high D2 affinity antipsychotics had an about twice higher risk of relapse than users of other types of antipsychotics. This higher risk of relapse after tapering should be regarded as a relevant factor when selecting an antipsychotic drug for people with a first psychotic episode. For patients using strong D2 antagonists after remission from a first psychotic episode, extra monitoring during tapering is required.
引用
- Gangadin SS, de Beer F, Wijnen B, et al. Risk of relapse during tapering of antipsychotic medication after a first psychotic episode: association with D2 receptor affinity but not with tapering speed. World Psychiatry. 2025. PMID: 40371797. doi:10.1002/wps.21315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。